IgA肾病的治疗进展  

Progress in Treatment of IgA Nephropathy

作　　者：张天怡 侯俊英[2] ZHANG Tianyi;HOU Junying(Affiliated Chifeng Clinical College of Inner Mongolia Medical University,Chifeng 024000,China;Department of Nephrology,Chifeng City Hospital,Chifeng 024000,China)

机构地区：[1]内蒙古医科大学赤峰临床医学院,内蒙古赤峰024000 [2]赤峰市医院肾内科,内蒙古赤峰024000

出　　处：《医学综述》2024年第11期1339-1343,1348,共6页Medical Recapitulate

摘　　要：IgA肾病是我国最常见的原发性肾小球疾病。近年随着医疗技术及人们生活水平的提高,原发性IgA肾病的发病人群呈年轻化趋势,发病率也逐渐升高。随着研究的深入,在传统优化支持治疗及免疫抑制治疗的基础上,针对IgA肾病发病机制不同位点的靶向治疗药物不断出现,且主要涉及黏膜免疫、补体活化、T细胞依赖或非T细胞依赖B细胞活化等方面。因此,全面了解IgA肾病的治疗进展、研发新型靶向药物,可以为IgA肾病患者的治疗提供更多选择。IgA nephropathy is the most common primary glomerular disease in China.In recent years,with the improvement of technology and people′s living standards,the incidence of primary IgA nephropathy is getting younger,and the incidence is gradually increasing.With the deepening of the research,on the basis of traditional optimal supportive therapy and immunosuppressive therapy,targeted therapeutic drugs targeting different sites of IgA nephropathy continue to emerge,mainly involving mucosal immunity,complement activation,T-cell-dependent or non-T-cell-dependent B-cell activation and other aspects.Therefore,a comprehensive understanding of the treatment progress of IgA nephropathy and the development of new targeted drugs can provide more options for the treatment of the patients.

关 键 词：IGA肾病 支持治疗 靶向治疗 药物机制 

分 类 号：R692.31[医药卫生—泌尿科学]